一般演題（口演）24 MET・RET

[O24-3] Telisotuzumab Vedotin in Asian Patients With c-Met Protein?Overexpressing Non-Squamous EGFR WT NSCLC

^○Hidehito Horinouchi¹, Jen-Yu Hung², Zhen-Yu Ding³, Se-Hoon Lee⁴, Chunling Liu⁵, Jim Looman⁶, Christine K. Ratajczak⁶, Hasan Alhasani⁶, Martha M. Li⁶, Summer Xia⁶, Shun Lu⁷ (1.National Cancer Center Hospital, Tokyo, Japan, 2.Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 3.Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China, 4.Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 5.The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang, China, 6.AbbVie Inc, North Chicago, IL, USA, 7.Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China)

アンコール演題